PortfoliosLab logoPortfoliosLab logo
MRNA vs. KR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MRNA vs. KR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and The Kroger Co. (KR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MRNA achieves a 69.24% return, which is significantly higher than KR's 4.64% return.


MRNA

1D
0.54%
1M
1.77%
YTD
69.24%
6M
69.42%
1Y
87.14%
3Y*
-26.94%
5Y*
-25.59%
10Y*

KR

1D
0.92%
1M
-1.98%
YTD
4.64%
6M
3.46%
1Y
0.76%
3Y*
13.84%
5Y*
13.21%
10Y*
8.32%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MRNA vs. KR - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
MRNA
Moderna, Inc.
69.24%-29.08%-58.19%-44.63%-29.28%143.11%434.10%28.09%-30.59%
KR
The Kroger Co.
4.64%4.25%36.91%4.99%0.44%45.41%11.90%7.90%-6.97%

Correlation

The correlation between MRNA and KR is -0.22, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.22

Correlation (3Y)
Calculated over the trailing 3-year period

-0.10

Correlation (5Y)
Calculated over the trailing 5-year period

-0.03

Correlation (All Time)
Calculated using the full available price history since Dec 7, 2018

0.04

The correlation between MRNA and KR shifts across timeframes, from -0.22 (1 year) to 0.04 (all time), reflecting how their relationship changes across market environments.

Fundamentals

EPS

MRNA:

-$8.16

KR:

$1.20

PS Ratio

MRNA:

8.78

KR:

0.29

Total Revenue (TTM)

MRNA:

$2.23B

KR:

$147.23B

Gross Profit (TTM)

MRNA:

-$309.00M

KR:

$33.42B

EBITDA (TTM)

MRNA:

-$3.02B

KR:

$5.29B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MRNA vs. KR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRNA
MRNA Risk / Return Rank: 7878
Overall Rank
MRNA Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
MRNA Sortino Ratio Rank: 7979
Sortino Ratio Rank
MRNA Omega Ratio Rank: 7575
Omega Ratio Rank
MRNA Calmar Ratio Rank: 7979
Calmar Ratio Rank
MRNA Martin Ratio Rank: 7676
Martin Ratio Rank

KR
KR Risk / Return Rank: 4242
Overall Rank
KR Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
KR Sortino Ratio Rank: 3939
Sortino Ratio Rank
KR Omega Ratio Rank: 3838
Omega Ratio Rank
KR Calmar Ratio Rank: 4444
Calmar Ratio Rank
KR Martin Ratio Rank: 4444
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MRNA vs. KR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and The Kroger Co. (KR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MRNAKRDifference
Sharpe ratioReturn per unit of total volatility

+1.23

Sortino ratioReturn per unit of downside risk

+1.83

Omega ratioGain probability vs. loss probability

1.24

1.03

+0.21

Calmar ratioReturn relative to maximum drawdown

2.34

0.08

+2.26

Martin ratioReturn relative to average drawdown

4.59

0.15

+4.43

MRNA vs. KR - Sharpe Ratio Comparison

The current MRNA Sharpe Ratio is 1.28, which is higher than the KR Sharpe Ratio of 0.06. The chart below compares the historical Sharpe Ratios of MRNA and KR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MRNA vs. KR - Drawdown Comparison

The maximum MRNA drawdown since its inception was -95.38%, which is greater than KR's maximum drawdown of -66.81%. Use the drawdown chart below to compare losses from any high point for MRNA and KR.


Loading charts...

Drawdown Indicators


MRNAKRDifference

Max Drawdown

Largest peak-to-trough decline

-95.38%

-66.81%

-28.57%

Max Drawdown (1Y)

Largest decline over 1 year

-35.51%

-19.44%

-16.07%

Max Drawdown (3Y)

Largest decline over 3 years

-86.58%

-19.44%

-67.14%

Max Drawdown (5Y)

Largest decline over 5 years

-95.38%

-31.07%

-64.31%

Max Drawdown (10Y)

Largest decline over 10 years

-46.25%

Current Drawdown

Current decline from peak

-89.70%

-13.95%

-75.75%

Average Drawdown

Average peak-to-trough decline

-57.06%

-22.44%

-34.62%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.06%

10.13%

+7.93%

Volatility

MRNA vs. KR - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 17.56% compared to The Kroger Co. (KR) at 9.04%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than KR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MRNAKRDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.56%

9.04%

+8.52%

Volatility (6M)

Calculated over the trailing 6-month period

48.82%

20.04%

+28.78%

Volatility (1Y)

Calculated over the trailing 1-year period

64.75%

27.54%

+37.21%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

66.49%

26.85%

+39.64%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

72.15%

28.94%

+43.21%

Dividends

MRNA vs. KR - Dividend Comparison

MRNA has not paid dividends to shareholders, while KR's dividend yield for the trailing twelve months is around 2.16%.


PositionTTM20252024202320222021202020192018201720162015
KR
The Kroger Co.
2.16%2.14%2.00%2.41%2.11%1.72%2.14%2.07%1.93%1.79%1.30%0.94%
MRNA
Moderna, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

MRNA vs. KR - Financials Comparison

This section allows you to compare key financial metrics between Moderna, Inc. and The Kroger Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00B20.00B30.00B40.00B50.00B20222023202420252026
389.00M
33.86B
(MRNA) Total Revenue
(KR) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MRNA and KR have a correlation of -0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MRNA has higher volatility (17.56%) compared to KR (9.04%). In terms of maximum drawdown, MRNA dropped -95.38% vs KR's -66.81%.

MRNA currently has the higher Sharpe Ratio (1.28 vs 0.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MRNA and KR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer